Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT01377389
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Phase 2
Completed
- Conditions
- Myeloproliferative Diseases
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT01375140
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The Effects of Ginseng on Cancer-Related Fatigue
Phase 1
Active, not recruiting
- Conditions
- Solid TumorsAdvanced Cancers
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 165
- Registration Number
- NCT01375114
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1
Completed
- Conditions
- Plasma Cell LeukemiaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT01372540
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1
Recruiting
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsRecurrent Burkitt LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeBurkitt-Like Lymphoma With 11q AberrationRecurrent B Acute Lymphoblastic LeukemiaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedRefractory B Acute Lymphoblastic LeukemiaRefractory Burkitt LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 276
- Registration Number
- NCT01371630
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Clearance Of Mucus In Stents (COMIS)
Not Applicable
Completed
- Conditions
- Respiratory FailureThromboembolic DiseaseLung NeoplasmsPneumoniaAcute Coronary SyndromesCardiac ArrhythmiaUnstable AnginaMyocardial Infarction
- Interventions
- Other: Normal SalineOther: Sodium Bicarbonate
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT01370278
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
Phase 2
Terminated
- Conditions
- Colorectal CancerColorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01367275
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
Phase 3
Completed
- Conditions
- Locally Advanced Malignant NeoplasmCervical CancerCervical Squamous Cell CarcinomaAdenosquamous CarcinomaAdenocarcinoma
- Interventions
- Radiation: ChemoradiationProcedure: Extraperitoneal laparoscopic lymphadenectomy (EPLND)
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT01365156
- Locations
- 🇺🇸
Lyndon B. Johnson General Hospital, Houston, Texas, United States
🇧🇪Vall d'Hebron Hospital, Brussels, Belgium
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Not Applicable
Recruiting
- Conditions
- Malignant NeoplasmStage I Oral Cavity Cancer AJCC v6 and v7Stage IIA Colorectal Cancer AJCC v7Stage III Hypopharyngeal Carcinoma AJCC v7Stage IVB Colorectal Cancer AJCC v7Pancreatic AdenocarcinomaStage I Major Salivary Gland Cancer AJCC v7Stage IIC Colorectal Cancer AJCC v7Stage III Laryngeal Cancer AJCC v6 and v7Stage IVA Hypopharyngeal Carcinoma AJCC v7
- Interventions
- Behavioral: Exercise InterventionOther: Questionnaire AdministrationOther: Health TelemonitoringOther: Quality-of-Life Assessment
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 590
- Registration Number
- NCT01365169
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2
Completed
- Conditions
- Adult Acute Lymphoblastic Leukemia in Complete RemissionBurkitt LeukemiaBurkitt LymphomaChildhood Acute Lymphoblastic Leukemia in Complete RemissionAcute Lymphoblastic LeukemiaCD20 PositiveLymphoblastic Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: Ofatumumab
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT01363128
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States